Epoch Investment Partners’s UroGen Pharma URGN Stock Holding History

Epoch Investment Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-132,439	Closed	-$1.46M	–	296
2025 Q1	$1.46M	Buy	132,439 +6,751	+5%	+$72K	0.01%	233
2024 Q4	$1.34M	Sell	125,688 -11,184	-8%	-$134K	0.01%	241
2024 Q3	$1.74M	Buy	+136,872	New	+$2.03M	0.01%	265

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Epoch Investment Partners's URGN Position: Q2 2025 in Review

Epoch Investment Partners sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 132,439 shares — an estimated $1.46M sold.

Epoch Investment Partners first reported a position in URGN in Q3 2024 and held it in 3 quarters. The position peaked at $1.74M in Q3 2024. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

Epoch Investment Partners reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
Epoch Investment Partners sold 132,439 UroGen Pharma shares in Q2 2025, an estimated $1.46M.
Epoch Investment Partners first reported a position in UroGen Pharma in Q3 2024 and held it in 3 quarters.
Epoch Investment Partners's UroGen Pharma position peaked at $1.74M in Q3 2024.
150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on Epoch Investment Partners's 13F filing for Q2 2025, filed 13 Aug 2025.